Source: Eur Respir J 2008; 32: 881-891
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Schermuly R. T., Stasch J-P., Pullamsetti S. S., Middendorff R., Muller D., Schluter K-D., Dingendorf A., Hackemack S., Kolosionek E., Kaulen C., Dumitrascu R., Weissmann N., Mittendorf J., Klepetko W., Seeger W., Ghofrani H. A., Grimminger F.. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008; 32: 881-891

Member's Comments

No comment yet.

Related content which might interest you: Pathways in pulmonary arterial hypertension: the future is here Source: Eur Respir Rev 2012 21: 321-327 Year: 2012 Gene polymorphisms of endothelial nitric oxide synthase in pulmonary arterial hypertension Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005 Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy Source: Eur Respir Rev 2009; 18: 35-41 Year: 2009 High-altitude pulmonary hypertension Source: Eur Respir Rev 2009; 18: 13-17 Year: 2009 Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension? Source: Eur Respir Rev 2009; 19: 68-71 Year: 2010 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 Correlation of inhaled nitric-oxide induced reduction of pulmonary artery pressure and vascular changes Source: Eur Respir J 2002; 20: 52-58 Year: 2002 Effect of the Asp298 variant of endothelial nitric oxide synthase on acute pulmonary vasodilator testing response in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006 Pathophysiology of pulmonary arterial hypertension Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=191 Year: 2004 A soluble guanylate cyclase stimulator, BAY 41-8543, preserves pulmonary artery endothelial function in experimental pulmonary embolism Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 1354-1360 Year: 2009 Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension Source: Eur Respir J, 56 (5) 2000522; 10.1183/13993003.00522-2020 Year: 2020 Expression of endothelial nitric oxide synthase (eNOS) and endothelin-1 (ET-1) in pulmonary arteries of patients with severe COPD Source: Annual Congress 2003 - Pathophysiology of the pulmonary circulation Year: 2003 The role of soluble guanylyl cyclase in chronic obstructive pulmonary disease Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension Source: Eur Respir J 2009; 33: 785-792 Year: 2009 Endogenous endothelins and nitric oxide in hypoxic pulmonary vasoconstriction Source: Eur Respir J 2003; 21: 19-24 Year: 2003 Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial Source: Eur Respir J 2013; 41: 853-860 Year: 2013 Upregulation of endothelial nitric oxide synthase in pulmonary artery of infants with pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 694s Year: 2004 Oestradiol ameliorates monocrotaline pulmonary hypertension via NO, prostacyclin and endothelin-1 pathways Source: Eur Respir J 2013; 41: 1116-1125 Year: 2013